Pharma Rep Focus

Cloud in pharma: Q&A with GlobalData thematic analyst

Pharmaceutical Technology

NOVEMBER 9, 2023

GlobalData analyst Jemima Walker discusses key topics around cloud computing for the pharmaceutical industry.

Pharma

Pharma Pharmaceutical

Cybersecurity in pharma: Q&A with GlobalData thematic analyst

Pharmaceutical Technology

OCTOBER 11, 2023

GlobalData analyst Wafaa Hasan discusses key topics around cybersecurity for the pharmaceutical industry.

Pharma

Pharma Pharmaceutical

Black participants make up just 3% in cancer clinical trials, says GlobalData

European Pharmaceutical Review

AUGUST 30, 2022

Diversity within the pharmaceutical sector and clinical trials continues to be a problem, according to a recent report by data and analytics company GlobalData. The post Black participants make up just 3% in cancer clinical trials, says GlobalData appeared first on European Pharmaceutical Review.

Food and Drug Administration

Food and Drug Administration Food Safety Pharmaceutical

GlobalData at ISPOR Europe in Vienna – come see our posters!

Pharmaceutical Technology

NOVEMBER 3, 2022

GlobalData is pleased to be attending the Professional Society for Health Economics and Outcomes Research (ISPOR) Europe Conference from 6–9 November 2022. The post GlobalData at ISPOR Europe in Vienna – come see our posters! Please look out for Gustav Ando, Milena Izmirlieva, Sara Trenti, Sara Cesarec and Elliot Trofimowicz.

Pharma

Pharma Leads Medical Pharmaceutical

Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report

Fierce Pharma

JUNE 16, 2023

But Eli Lilly is quickly gaining ground and is primed to become the market leader with its GLP-1 treatment Mounjaro, according to GlobalData. . | In the battle for diabetes and obesity superiority, Novo Nordisk holds a head start as the original developer of the metabolism-regulating treatment semaglutide.

Leads

Leads Marketing

Amgen, Regeneron and AbbVie join Lilly and Novo Nordisk in posting largest Q3 market-cap gains: report

Fierce Pharma

OCTOBER 30, 2023

But much less expected were the market-cap rallies of Amgen (22.1%), Regeneron (14.9%) and AbbVie (13.1%), according to figures compiled by GlobalData. That didn | It was no surprise that GLP-1 drugmakers Eli Lilly and Novo Nordisk saw market-cap gains of 16.1% in the third quarter.

Marketing

Marketing Biopharma Sales

Could novel antibiotic successfully treat a ‘priority 1 pathogen’?

European Pharmaceutical Review

JANUARY 19, 2024

According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. An example is Fetroja (cefiderocol sulfate tosylate).

Manufacturing

Manufacturing Medicine Leads Pharmaceutical

Four ways the vaccine rush will define infectious disease trends for CROs in 2024

Pharmaceutical Technology

MAY 10, 2024

GlobalData examines four of the key trends affecting contract research organizations (CROs) involved with infectious diseases.

CRISPR technologies fuelling haematological innovations

European Pharmaceutical Review

APRIL 12, 2024

There has been a “notable” rise in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology for gene therapies over the past five years, according to data and analytics firm GlobalData. These agreements have amassed a total deal value of $21 billion.

Food and Drug Administration

Food and Drug Administration Medicine Food Pharmaceutical

Experts Believe Gene Therapy Offers Potential to Impact Gaucher Disease Market

Pharmaceutical Technology

NOVEMBER 21, 2023

According to several key opinion leaders (KOLs) interviewed by GlobalData, pipeline gene therapy holds the greatest potential to transform the Gaucher disease landscape

Marketing

Chinese companies lead ADC pipeline

Pharmaceutical Technology

MAY 1, 2024

Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class that leading data and analytics company GlobalData forecasts will generate more than $45bn in revenue by 2030.

Leads

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval

Pharmaceutical Technology

MAY 17, 2024

According to GlobalData, Phase… Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.

(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval

Pharmaceutical Technology

OCTOBER 27, 2023

According to GlobalData,… (CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.

Research predicts 2029 small molecule oncology market leaders

European Pharmaceutical Review

OCTOBER 12, 2023

This represents approximately 40 percent of the total NSCLC market, stated GlobalData. Sales for AstraZeneca’s Tagrisso are anticipated to exceed $7 billion and hold a 48 percent share of the market of small molecules in lung cancer treatment by 2029, according to data and analytics company GlobalData. percent by 2029.

Marketing

Marketing Sales Medicine FDA

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

According to GlobalData, Phase… PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor.

Artificial Intelligence related patent filings increased in the pharmaceutical industry in Q2 2023

Pharmaceutical Technology

AUGUST 9, 2023

The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.

Pharmaceutical

Artificial Intelligence related patent filings increased in the pharmaceutical industry in Q2 2023

Pharmaceutical Technology

AUGUST 9, 2023

The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.

Pharmaceutical

The changing of the guard is expected in the Crohn’s disease marketplace

Pharmaceutical Technology

SEPTEMBER 1, 2023

As per GlobalData, AbbVie has remained the Crohn’s disease market leader over the last five years, with Humira sales of $2.7bn in 2022 in 8MM.

Sales

Sales Marketing

RSV Designations Reached All Time High in 2022, Data Shows

PharmExec

OCTOBER 27, 2023

Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.

Marketing

ADC oncology therapy market to value over $36b by 2029

European Pharmaceutical Review

AUGUST 9, 2023

According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments. More investment in research and development is expected in the future, noted GlobalData. Daiichi Sankyo was predicted to remain the dominant player in this market.

Marketing

Marketing Pharmaceutical Manufacturing

Which drugs are most likely to be approved in Cryopyrin-Associated Periodic Syndromes?

Pharmaceutical Technology

MARCH 27, 2024

Cryopyrin-Associated Periodic Syndromes disease is an indication for drug development with over 10 pipeline drugs currently active according to GlobalData.

Which drugs are most likely to be approved in Complicated Intra-Abdominal Infections?

Pharmaceutical Technology

MARCH 27, 2024

Complicated Intra-Abdominal Infections disease is an indication for drug development with over 20 pipeline drugs currently active according to GlobalData.

Cell & gene therapy: the leading companies in rAAV production technology revealed

Pharmaceutical Technology

NOVEMBER 6, 2023

GlobalData uncovers the leading innovators in rAAV production technology for the pharmaceutical industry.

Leads

Leads Pharmaceutical

Conjunctivitis drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 59 drugs in development for Conjunctivitis by 51 companies/universities/institutes. The top development phase for Conjunctivitis is preclinical, with 20 drugs in that stage.

Retinopathy drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 198 drugs in development for Retinopathy by 163 companies/universities/institutes. The top development phase for Retinopathy is preclinical, with 131 drugs in that stage.

Which drugs are most likely to be approved in Respiratory Tract Infections?

Pharmaceutical Technology

MARCH 27, 2024

Respiratory Tract Infections disease is an indication for drug development with over 120 pipeline drugs currently active according to GlobalData.

Blepharospasm drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Blepharospasm by four companies/universities/institutes. The top development phase for Blepharospasm is phase ii, with two drugs in that stage.

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

AUGUST 21, 2023

Data and analytics company GlobalData has reported a rise from $3.49 percent increase in market capitalisation,” commented Alison Labya, MSc, Business Fundamentals Analyst at GlobalData. percent increase in market capitalisation,” commented Alison Labya, MSc, Business Fundamentals Analyst at GlobalData. trillion in Q2 2023.

Biopharma

Biopharma Marketing Sales Medicine

Experts flag concerns with drug compliance in osteoporosis landscape

Pharmaceutical Technology

MARCH 26, 2024

KOLs interviewed by GlobalData emphasised urgent action to address inconsistent drug compliance rates in the osteoporosis disease landscape.

Financial factors to support and challenge Pharma in 2024

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Pharma

Pharma Medicine Government Marketing

Retinal Degeneration drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 76 drugs in development for Retinal Degeneration by 63 companies/universities/institutes. The top development phase for Retinal Degeneration is preclinical, with 40 drugs in that stage.

Meibomian Blepharitis drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Meibomian Blepharitis by six companies/universities/institutes. The top development phase for Meibomian Blepharitis is phase ii, with three drugs in that stage.

Inherited Mitochondrial Disorders drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 22 drugs in development for Inherited Mitochondrial Disorders by 19 companies/universities/institutes. The top development phase for Inherited Mitochondrial Disorders is preclinical, with 13 drugs in that stage.

Lewy Body Dementia drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 46 drugs in development for Lewy Body Dementia by 36 companies/universities/institutes. The top development phase for Lewy Body Dementia is preclinical, with 21 drugs in that stage.

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. mRNA stability and delivery specificity are two of the main obstacles hindering progress for oncology therapy approvals, according to Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData.

Marketing

Marketing Sales Competition Pharmaceutical

Adalimumab biosimilars shaping market, research states

European Pharmaceutical Review

AUGUST 4, 2023

According to data and analytics company GlobalData , Boehringer Ingelheim’s Cyltezo has demonstrated the intersection of price and regulation in the biosimilars market. “Of There are at present, nine US Food and Drug Administration (FDA)-approved agents, GlobalData stated. GlobalData noted that more are expected.

Marketing

Marketing Food and Drug Administration Food Medicine

Gliosarcoma drugs in development, 2023

Pharmaceutical Technology

NOVEMBER 30, 2023

GlobalData tracks 49 drugs in development for Gliosarcoma by 39 companies/universities/institutes. The top development phase for Gliosarcoma is phase i, with 22 drugs in that stage.

Which drugs are most likely to be approved in Labor And Delivery?

Pharmaceutical Technology

MARCH 27, 2024

Labor And Delivery disease is an indication for drug development with over 10 pipeline drugs currently active according to GlobalData.

Gastroesophageal (GE) Junction Carcinomas drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 150 drugs in development for Gastroesophageal (GE) Junction Carcinomas by 115 companies/universities/institutes. The top development phase for Gastroesophageal (GE) Junction Carcinomas is phase ii, with 72 drugs in that stage.

Choriocarcinoma (Gestational Trophoblastic Neoplasia) drugs in development, 2023

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) by four companies/universities/institutes. The top development phase for Choriocarcinoma (Gestational Trophoblastic Neoplasia) is phase i, with four drugs in that stage.

Biopharma could reap benefits from SVB UK acquisition

European Pharmaceutical Review

MARCH 31, 2023

Following the collapse of Silicon Valley Bank (SVB), HSBC’s acquisition of Silicon Valley Bank (SVP) UK may offer new opportunities for biopharmaceutical companies, according to data and analytics firm, GlobalData. The analytics group added that other European biopharmaceutical companies also expect to recover their deposits.

Biopharma

Biopharma Pharma Networking Marketing

Which drugs are most likely to be approved in Pneumonia?

Pharmaceutical Technology

MARCH 27, 2024

Pneumonia disease is an indication for drug development with over 230 pipeline drugs currently active according to GlobalData.

Who’s saying what? Cybersecurity mentions in company filings of pharmaceutical industry increased by 113% in Q1 2023

Pharmaceutical Technology

MAY 9, 2023

The global pharmaceutical industry experienced a 113% rise in company filings mentions of cybersecurity in Q1 2023 compared with the previous quarter, with the highest share accounted for by Alnylam Pharmaceuticals with 114% year-on-year increase, according to GlobalData’s analysis of over 667 pharmaceutical company filings.

Pharmaceutical

Pharmaceutical Healthcare Healthcare Leads

Which drugs are most likely to be approved in Cough?

Pharmaceutical Technology

MARCH 27, 2024

Cough disease is an indication for drug development with over 40 pipeline drugs currently active according to GlobalData.

Cloud in pharma: Q&A with GlobalData thematic analyst

Cybersecurity in pharma: Q&A with GlobalData thematic analyst

Trending Sources

Black participants make up just 3% in cancer clinical trials, says GlobalData

GlobalData at ISPOR Europe in Vienna – come see our posters!

Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report

Amgen, Regeneron and AbbVie join Lilly and Novo Nordisk in posting largest Q3 market-cap gains: report

Could novel antibiotic successfully treat a ‘priority 1 pathogen’?

Four ways the vaccine rush will define infectious disease trends for CROs in 2024

CRISPR technologies fuelling haematological innovations

Experts Believe Gene Therapy Offers Potential to Impact Gaucher Disease Market

Chinese companies lead ADC pipeline

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval

(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval

Research predicts 2029 small molecule oncology market leaders

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

Artificial Intelligence related patent filings increased in the pharmaceutical industry in Q2 2023

Artificial Intelligence related patent filings increased in the pharmaceutical industry in Q2 2023

The changing of the guard is expected in the Crohn’s disease marketplace

RSV Designations Reached All Time High in 2022, Data Shows

ADC oncology therapy market to value over $36b by 2029

Which drugs are most likely to be approved in Cryopyrin-Associated Periodic Syndromes?

Which drugs are most likely to be approved in Complicated Intra-Abdominal Infections?

Cell & gene therapy: the leading companies in rAAV production technology revealed

Conjunctivitis drugs in development, 2023

Retinopathy drugs in development, 2023

Which drugs are most likely to be approved in Respiratory Tract Infections?

Blepharospasm drugs in development, 2023

Biopharma sees strong Q2 2023 market cap growth

Experts flag concerns with drug compliance in osteoporosis landscape

Financial factors to support and challenge Pharma in 2024

Retinal Degeneration drugs in development, 2023

Meibomian Blepharitis drugs in development, 2023

Inherited Mitochondrial Disorders drugs in development, 2023

Lewy Body Dementia drugs in development, 2023

$2 billion mRNA-based oncology therapy market anticipated by 2029

Adalimumab biosimilars shaping market, research states

Gliosarcoma drugs in development, 2023

Which drugs are most likely to be approved in Labor And Delivery?

Gastroesophageal (GE) Junction Carcinomas drugs in development, 2023

Choriocarcinoma (Gestational Trophoblastic Neoplasia) drugs in development, 2023

Biopharma could reap benefits from SVB UK acquisition

Which drugs are most likely to be approved in Pneumonia?

Who’s saying what? Cybersecurity mentions in company filings of pharmaceutical industry increased by 113% in Q1 2023

Which drugs are most likely to be approved in Cough?

Stay Connected